Drawing for POWERED BY BIOHM

USPTO serial 87757230

POWERED BY BIOHM

Reviewed by CopyMark Law Group

Reg. 6707595Status 700Registered
Filing date
Status date
Registration date
Apr 19, 2022
Examiner
SMITH, CYNTHIA RINALDI
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with POWERED BY BIOHM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lisa C. Pavento

Lisa C. Pavento Meunier Carlin & Curfman LLC999 Peachtree St. NE, Suite 1300Atlanta, GA 30309United States

Goods and services

ClassDescriptionStatusFirst use
001Food products containing probiotic compositions, namely, probiotic bacteria and probiotic bacterial cultures for use as a food additive for food manufacturing; human food products containing probiotic compositions, namely, probiotic bacteria and probiotic bacterial cultures for use as a food additive for food manufacturing; animal food products containing probiotic compositions, namely, nutritional additives for use in manufacturing animal feedACTIVEFeb 17, 2022
005Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use, and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; beverages containing probiotic compositions for use as a nutritional supplement; food supplements containing probiotic compositions; human food supplements products containing probiotic compositions; animal food products containing probiotic compositions, namely, probiotic animal feed; dietary supplement drink mixes, namely, probiotic compositions in the form of mixes to added to beverages; dietary supplements in the nature of probiotic compositions for mixing with cerealACTIVEFeb 17, 2022

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 21, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 21, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 21, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 15, 2023ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Apr 19, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 15, 2022SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Mar 13, 2022CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Mar 1, 2022SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Feb 18, 2022IUAFUSE AMENDMENT FILED—
Feb 18, 2022EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Aug 10, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 9, 2021EX5GSOU EXTENSION 5 GRANTED—
Aug 6, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jul 28, 2021EXT5SOU EXTENSION 5 FILED—
Jul 28, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 17, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 15, 2021EX4GSOU EXTENSION 4 GRANTED—
Feb 15, 2021EXT4SOU EXTENSION 4 FILED—
Feb 15, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 5, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 5, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 5, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 5, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 5, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 21, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 19, 2020EX3GSOU EXTENSION 3 GRANTED—
Aug 19, 2020EXT3SOU EXTENSION 3 FILED—
Aug 19, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 28, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 27, 2020EX2GSOU EXTENSION 2 GRANTED—
Feb 27, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 18, 2020EXT2SOU EXTENSION 2 FILED—
Feb 18, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 18, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 20, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 16, 2019EX1GSOU EXTENSION 1 GRANTED—
Aug 16, 2019EXT1SOU EXTENSION 1 FILED—
Aug 16, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 19, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 30, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Dec 25, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 25, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 5, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 12, 2018ALIEASSIGNED TO LIE—
Oct 28, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 26, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 26, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 26, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 30, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 30, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 30, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 26, 2018DOCKASSIGNED TO EXAMINER—
Jan 29, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—

Frequently asked questions

Related guidance